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Abstract
Background: Accumulating evidence supports the theory that expression of CD127 on CD8 T cells during the
process of antiviral immune response indicates a subset of effect CD8 T cells that successfully develop into fully
protective memory. CD8 T cells expression of CD127 may be used as a predictor to evaluate disease status in
chronic viral infection. The aim of this study was to investigate the CD127 expression level on different subsets of
CD8 T cell and explore the relationship between CD127 expression on CD8 memory T cells and serum hepatitis B
virus (HBV) DNA and hepatitis B e antigen (HBeAg) levels in patients with chronic hepatitis B (CHB). We also aimed
to investigate the CD127 expression pattern on CD8 memory T cells of CHB patients who were treated with
Telbivudine.
Methods/Results: Twenty HBeAg-positive CHB patients were selected and treated with telbivudine 600 mg/day
for 48 weeks. The memory CD8 T cells were characterized by expression of CD45RA and CD27 markers. CD127
expression on the CD8 T-cell surface was measured by four-colour flow cytometry. Our results showed that CD127
expression on memory CD8 T cells was reduced in CHB patients. There was a strong negative correlation between
CD127 expression on memory CD8 T cells and serum HBV DNA and HBeAg levels in CHB patients. Moreover,
successful antiviral therapy increased CD127 expression on CD8 memory T cells as well as on HBV-specific CD8 T
cells in CHB patients.
Conclusion: These results suggest that diminished CD127 expression on CD8 memory T cells of CHB patients is a
potential mechanism explaining cellular immune function impairment in CHB infection, and that CD127 expression
on CD8 memory T cells is a useful indicator for evaluating the effects of anti-HBV therapy.
Introduction
Chronic hepatitis B virus (HBV) infection remains a
serious global health problem. It affects approximately
350 million people worldwide and more than 130 million
in Chian[1]. It is widely accepted that the adaptive
immune responses, particularly the cellular immune
response, mediate clearance of HBV. Unfortunately, in
most patients, chronic HBV infection leads to severe
abnormalities of CD8 T-cell function, as shown by a
low level of antiviral cytokines and impaired cytotoxic
T-lymphocyte (CTL) activity [2].
Naive CD8 T cells that encounter their cognate antigen
undergo a complex process of maturation and differentia-
tion that ultimately leads to the generation of long-lived
memory CD8 T cells, which mediate immune production
from subsequent challenge with the same antigen [3].
Memory CD8 T cells are characterized by their abilities to
survive homeostatically in the absence of antigen and pro-
liferate vigorously upon antigenic re-encounter. Memory
CD8 T cells are easily activated upon antigen rechallenge,
in which situation they quickly produce antiviral cytokines
or cytotoxic molecular [4,5].
Interleukin (IL)-7 signalling is essential to CD8 T-cell
proliferation and function. The IL-7 receptor (IL-7R), a
heterodimer, is composed of a unique a chain (CD127)
and a common g chain (CD132) [6]. During viral infec-
tion, CD127 expression on CD8 T cells occurs only
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T-cell help is available [7]. Persistent viral antigen load
suppresses CD127 expression on primed T cells and
correlates with exhaustion of a previously stable primed
T-cell population [8]. Studies on patients with acute
HBV infection showed that CD127 expression on HBV-
specific CD8 T cells increased markedly after viral clear-
ance [9].
In the present study, we demonstrated that CD127
expression on CD8 memory T cells was reduced in
patients with chronic hepatitis B (CHB). There was a
strong negative correlation between CD127 expression
on CD8 memory T cells and serum HBV DNA and
hepatitis B e antigen (HBeAg) levels in these patients.
Moreover, successful antiviral therapy increased CD127
expression on CD8 memory T cells as well as on HBV-
specific CD8
+ T cells in patients with CHB. These
results suggest that CD127 expression is a potential
indicator for evaluating the effects of anti-HBV therapy.
Materials and methods
Patients
This study was approved by the Ethics Review Commit-
tee of the First Affiliated Hospital, School of Medicine,
Zhejiang University (Hangzhou, Zhejiang, China). The
diagnosis of CHB was made according to the diagnostic
standards from the National Program for Prevention and
Treatment of Viral Hepatitis. A total of 20 HLA-A2
+
patients with CHB (8 women and 12 men; mean age 27
years) were enrolled in the study. Human leucocyte anti-
gen (HLA) typing was performed using polymerase chain
reaction (PCR) amplification with sequence-specific pri-
mers, and it was confirmed by flow cytometry.
Hepatitis B surface antigen (HBsAg), HBeAg, anti-
HBc, anti-HBe and anti-HBs were quantified by radio-
immunoassay (Abbott Laboratories, Abbott Park, IL,
USA). HBV DNA was measured using the Amplicor
HBV test (Roche Diagnostics, Basel, Switzerland) with a
detection limit of 300 copies/mL. All patients were
HBeAg positive and had never received anti-HBV ther-
apy before.
At baseline, the average serum HBV DNA of the
20 patients was 7.8 ± 0.09 log10 copies/mL [median: (7.9
5.0-9.8) log10 copies/mL], and the serum alanine amino-
transferase (ALT) was 174.6 ± 7.78 IU/L [median: 113
(99-567) IU/L]. All patients received telbivudine 600
mg/day for 48 weeks. The serum ALT level, HBsAg,
HBeAg, anti-HBc, anti-HBe, anti-HBs and HBV DNA
were tested every 12 weeks during the telbivudine ther-
apy. Healthy donors (n = 10) were included as controls.
Flow cytometry
Peripheral blood mononuclear cells (PBMC) were iso-
lated from ethylenediaminetetraacetic acid (EDTA)
anticoagulated blood samples on a Ficoll-Histopaque
density gradient. After isolation, cells were washed twice
in phosphate-buffered saline (PBS) and studied immedi-
ately. CD127, CD8, CD27 and CD45RA expression on
the PBMC was detected by direct staining.
CD127 expression on HBV-specific CD8
+ T cells was
performed as described previously [10]. Briefly, PBMC
were stained with surface PC5-anti-CD8 (BD Pharmingen,
San Diego, CA, USA) and pentamer+ CD8 T cells were
detected by staining with phycoerythrin (PE)-labelled
pentameric peptide-HLA2 complex (ProImmune, Oxford,
UK) containing HBV Core 18-27 (FLPSDFFPSV) and
HBV Core 18-27 (FLPSDFFPSI). Gated on CD8 T cells,
CD127 expression on HBV-specific CD8 T cells was ana-
lyzed by fluorescein isothiocynate (FITC)-anti-CD127 and
PE-labelled pentamers. Cells were washed three times
with PBS, and 1 × 10
6 events in the lymphogate were
collected by flow cytometry (EPICSXL; Coulter, Fullerton,
CA, USA). Data were analyzed using CellQuest software
(Coulter).
Statistical analysis
The Wilcoxon matched pairs test and the Mann-Whitney
test of SPSS version 12.0 were used to assess differences
among groups. Spearman correlation analysis was per-
formed between CD127 expression and serum HBV
DNA and HBeAg levels. P- v a l u e sl e s st h a n0 . 0 5w e r e
considered statistically significant.
Results
CD127 expression on memory CD8 T cells was reduced in
patients with chronic hepatitis B
Ex vivo expression of CD127 by different CD8 T lympho-
cyte subsets taken from patients with CHB were checked
by flow cytometry. As indicated in Fig. 1a, naive CD8
T cells (CD45RA
+CD27
+) from CHB patients showed a
high percentage of CD127
+ cells, as did the cells from
healthy controls. When the expression of CD127 was
examined in memory CD8 T cells (CD45RA
-CD27
+) and
effector CD8 T cells (CD45
-RACD27
-), we found signifi-
cant decrease of CD127 expression in CHB patients com-
pared with healthy controls. Terminally differentiated
effector CD8 T cells (CD45RA
+CD27
-) from both CHB
patients and healthy controls expressed little CD127, as
indicated in Fig. 1b.
To determine whether the decreased percentage of
CD8
+CD127
+ memory T cells reflected an absolute
reduction of these cells or increase of CD8
+CD127
-
memory T cells, we calculated the absolute counts of
CD127
+ and CD127
- memory cells in the total CD8
T cells as well as in the naive- and memory-cell subsets.
As indicated in Fig. 2a, the absolute number of CD8
+
T cells expressing CD127 was similar in CHB patients
and in healthy controls. But the absolute number of
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Page 2 of 6Figure 1 Ex vivo expression of CD127 by memory CD8 T cells taken from chronic hepatitis B (CHB) patients. (a) CD127 expression by CD27
+CD45RA
+ naive CD8 T cells. Results are shown for one healthy control and two CHB patients. (b) Proportion of CD127
+ lymphocyte cells in the
memory (CD45RA
-CD27
+), effector (CD45RA
-CD27
-) and terminally differentiated effector (CD45RA
+CD27
-) CD8 T-cell subsets in healthy controls
and CHB patients (n = 20 for each group). Healthy controls (gray bar); CHB patients(black bar). *P < 0.05 when compared to healthy controls.
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Figure 2 Decreased CD127 expression on memory CD8 T cells from chronic hepatitis B (CHB) patients. (a) Representative dot plots showing the
expression of CD127 on CD8 T cells in one CHB patient and one healthy control. The numbers on the right indicate the percentages of CD8 T cells that
are CD127
+ and CD127
-. (b) Absolute counts per cubic millimetre of total CD127
- lymphocytes in naive, memory, effector and terminally differentiated
CD8 lymphocytes from each study group. Healthy controls (gray bar); CHB patients(black bar). *P <0 . 0 5w h e nc o m p a r e dt oh e a l t h yc o n t r o l s .
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+CD127
- T cells increased significantly in CHB
patients compared with healthy controls. Importantly,
t h ea b s o l u t eC D 1 2 7
- memory T-cell count increased
markedly in CHB patients as well, while only a small
increase in the number of CD127
- naive T cells was
detected in the same group of patients (Fig. 2b). These
r e s u l t si m p l yt h a tH B Vi n f e c t i o ni sa s s o c i a t e dw i t ha
marked up-regulation of memory T cells that have
decreased expression of CD127.
Relationship between CD127 expression on memory CD8
T cells and serum HBV DNA and HBeAg levels in patients
with chronic hepatitis B
We next investigated a possible relationship between the
CD127 expression of CD8 memory T cells of CHB
patients and the main viral markers of HBV infection:
serum HBV DNA and HBeAg. There was a strong nega-
tive correlation between CD127 expression on CD8
memory T cells and these markers in CHB patients, as
indicated in Fig. 3.
Antiviral therapy increased CD127 expression on CD8
memory T cells in patients with chronic hepatitis B
We selected 20 HBeAg-positive CHB patients who were
treated with telbivudine 600 mg/day for 48 weeks. After
48 weeks of treatment, 6 patients became HBV DNA
negative by PCR assay and had HBeAg seroconversion.
These six patients were defined as ‘well responders’.F o u r
patients whose serum HBV DNA levels remained at
more than 5 log10 copies/mL and HBeAg remained posi-
tive at Week 48 were defined as ‘non-responders’.T h e
other ten patients were defined as ‘partial responders’.
We dynamically compared the proportion of CD127
expression on the memory CD8 T cells among the well
responders, partial responders and non-responders. As
indicated in Fig. 4, telbivudine significantly increased
CD127 expression on memory CD8 T cells from well
responders compared with non-responders (P < 0.05).
Emergence of CD127 HBV-specific CD8
+ T cells after
successful antiviral treatment
We compared the expression of CD127 on HBV-specific
CD8
+ T cells from CHB patients before and after telbi-
vudine treatment. As indicated in Fig. 5A and 5B,
CD127 expression increased markedly in HBV-specific
CD8 T cells in telbivudine responders compared with
non-responders (P < 0.05).
Discussion
In our study, we demonstrated that CD127 expression
on memory CD8 T cells was reduced in patients with
CHB. There was a strong negative correlation between
CD127 expression on memory CD8 T cells and serum
HBV DNA and HBeAg levels in CHB patients.
Figure 3 The relationship between CD127 expression on
memory CD8 T cells and serum hepatitis B virus (HBV) DNA
and hepatitis B e antigen (HBeAg) levels in chronic hepatitis B
(CHB) patients. (a) Expansion of CD127
+ memory CD8 T cells is
correlated inversely with serum HBV DNA level in CHB patients. (b)
Expansion of CD127
+ memory CD8 T cells is correlated inversely
with serum HBeAg level in CHB patients. All analyses were
performed on the 20 CHB patients described in the Materials and
Methods.
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Figure 4 Antiviral therapy increases CD127 expression on CD8
memory T cells in chronic hepatitis B (CHB) patients. The mean
expression of CD127 on CD8 memory T cells. The analysis was
performed on 20 CHB patients treated with telbivudine at 0, 24 and
48 weeks. Statistical analyses were performed among 6 well
responders (black bar), 10 partial responders (gray bar) and 4 non
responders (white bar) (*P < 0.05).
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increased CD127 expression on CD8 memory T cells as
well as on HBV-specific CD8 T cells in CHB patients.
It is widely accepted that CD8 T cells play an essential
role in the immune response to viral infection. In suc-
cessful responses to acute HBV, hepatitis C virus (HCV)
and lymphocytic choriomeningitis virus (LCMV) infec-
tion, the up-regulation of CD127 expression on CD8 T
cells is closely associated with the downregulation of
CD38 and PD-1 and the upregulation of CCR7 expres-
sion [9,11,12]. All occurred in concert with resolution of
disease and containment of viral antigen, supporting the
theory that the emergence of CD127 is governed by with-
drawal of antigenic stimulation. Colle et al. [13] reported
that human immunodeficiency virus (HIV) infection was
associated with a decrease in the proportion of CD127
+
cells among memory CD8 T lymphocytes, which resulted
in a higher CD127
- CD8 T cells count in patients with
HIV infection. There was a strong negative correlation
between CD127 expression on CD8 T cells and HIV viral
load [14]. All of these results support the hypothesis that
high CD127 expression on human CD8 T cells is specific
for cleared virus [e.g. influenza virus, respiratory syncytial
virus (RSV) and acute HBV infection] while low CD127
expression on human CD8 T cells is specific for persist-
ing virus [e.g. HIV, cytomegalovirus (CMV), HCV and
HBV] [15].
Recently some reports have suggested that CD127
might be a useful marker for predicting response to
antiviral therapy in HIV- and HCV-infected patients.
Badr et al. [11] reported that during HCV infection,
early therapeutic intervention with pegylated (PEG)-
interferon (IFN)-a rescued long-lived, polyfunctional
memory CD8 T cells expressing high levels of CD127
and Bcl-2 (CD127
hiBcl
hi). In contrast, HCV-specific CD8
T cells in acute infections evolving to chronicity
expressed low levels of CD127 and Bcl-2, exhibited
diminished proliferation and cytokine production, and
eventfully disappeared from the periphery. Colle et al.
[13] also reported that CD127 was increased in memory
CD8 T lymphocytes from HAART patients. Our longi-
tudinal study indicated that successful antiviral therapy
with telbivudine increased CD127 expression on CD8
memory T cells as well as on HBV-specific CD8 T cells
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Figure 5 The emergence of CD127 hepatitis B virus (HBV)-specific CD8
+ T cells after successful antiviral treatment. Surface staining of
HBV-specific CD8 T cells was performed using a HBV multimer [A. HBV Core 18-27 (FLPSDFFPSV), B. HBV Core 18-27 (FLPSDFFPSI)] and antibody
to CD127, as described in the Materials and Methods. Data are shown as the percentage of multimer-positive CD8 T cells from 6 well responders
(black bar) and 4 non responders (white bar) of CHB patients treated with telbivudine at 0 and 48 weeks respectively. (*P < 0.05).
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Page 5 of 6in CHB patients. These consistent results clearly suggest
that measurement of CD127 expression might be useful
for predicting response to antiviral therapy.
In chronic HBV-infected patients, the frequency and
function of circulating and intrahepatic antiviral T-cell
responses is inversely proportional to the level of HBV
DNA [16,17]. Nucleoside analogues are known to inter-
fere with viral replication, directly lowering HBV DNA
levels, but whether they influence the development of
effective memory T-cell differentiation and function has
not been proven. Our findings indicate that treatment-
induced suppression of HBV replication resulted in
upregulation of CD127 expression on memory CD8 T
cells in all well responders to telbivudine, but not in
non-responders. These comparison results obtained in
the responders and non-responders to antiviral therapy
support the notion that increased expression of CD127
on memory CD8 T cells is linked to successful inhibi-
tion of viraemia. These results indicate measurement of
CD127 expression on memory CD8 T cells may be use-
ful to guide antiviral therapy in patients with CHB.
However, longitudinal studies are required to draw a
clear conclusion on this matter.
Taken together, our results suggest the mechanism
linking HBV replication and abnormalities in CD8 T-
cell function in patients with CHB. We also demonstrate
a strong negative correlation between HBV viraemia and
CD127 expression in memory CD8 T cells. Telbivudine-
induced inhibition of HBV replication resulted in signifi-
cant upregulation of CD127 expression in memory CD8
T cells, reducing its negative influence on CD8 T cells’
activation and function in CHB patients. Most impor-
tant, we demonstrate successful antiviral treatment can
rescue such a functional signature on memory CD8
T cells, which will indicate to achieve sustained inhibi-
tion of HBV replication and resolution of chronic liver
disease [18].
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